Managed Care
Disease
Management

Peer-Reviewed Articles from Managed Care

Research Articles from Managed Care

Navin K. Singh, MD ; Nancy L. Reaven, MA ; Susan E. Funk, MBA

There was little difference between the options in terms of the frequency and cost of return visits. Patients receiving one-stage reconstructions returned slightly less often for breast-related services during the first 18 months after reconstruction, but the difference was not statistically significant.

Donald W. Bradley, MD ; Gwen Murphy RD, PhD ; Linda G. Snetselaar, RD, PhD, LD ; Esther F. Myers, PhD, RD, FADA ; Laura G. Qualls, MHA
Overweight or obese patients who participated in a medical nutrition therapy benefit sponsored through their insurer were compared with individuals who did not participate. Outcomes, including weight change, body mass index, waist circumference, and physical exercise, were collected at baseline and 2 years later.
Nicole C. Ferko MSc ; Natalie Borisova PhD ; Parisa Airia, PhD ; Daniel T Grima, MSc ; Melissa F Thompson, MBA
Using case studies, researchers assess the effect of rebate rates on the cost-effectiveness of two oral bisphosphonates that are competing for tier 2 positioning
Juliana Meyers, MA ; Sean Candrilli, PhD ; Richard Allen, PhD ; Ranjani Manjunath, MPH ; Michael Calloway, PhD

The researchers find that the costs of treating restless legs syndrome are fairly low, relative to the improved symptoms and associated health care outcomes, and are mainly attributable to prescription medication. Health plans are encouraged to expand coverage to reduce the associated suffering and costs.

John Barron, PharmD ; Ralph Turner, PhD ; Michael Jaeger, MD ; Wallace Adamson, MD ; Joseph Singer, MD

Patients treated with oral linezolid, covered under the pharmacy benefit, had lower re-hospitalizations and emergency room visits than patients treated with vancomycin or daptomycin, covered under the medical benefit

Setareh A. Williams, PhD ; Erin K. Buysman, MS ; Erin M. Hulbert, MS ; Joette Gdovin Bergeson, PhD ; Bin Zhang, MD ; John Graham, PharmD

This study verifies, as defined by current guidelines, that initial treatment with fixed dose combinations (FDC) is associated with a better likelihood of HbA1c goal attainment and lower health care resource use and costs.

James P. Reichmann, MBA ; Michael S. Kirkbride, BSc, Pharm D

A review of the available research identifies payment for services in the absence of high-quality scientific evidence and presents an opportunity to use evidence-based medicine to develop a clinical coverage guideline

Debra Wertz, PharmD ; Likun Hou, MS ; Andrea DeVries, PhD ; Leon Dupclay Jr., PharmD, PhD ; Frannie McGowan, PharmD, CDE ; Barry Malinowski, MD ; Mark J. Cziraky, PharmD, FAHA
The program showed significant improvements in all diabetes and hypertension-related clinical measures
Eric Q. Wu, PhD ; Rym Ben-Hamadi, MSc ; Mei Lu, MS ; Nicolas Beaulieu, MA ; Andrew P. Yu, PhD ; M. Haim Erder, PhD
Escitalopram patients in a Florida Medicaid population had better treatment persistence and lower total health care costs than patients prescribed citalopram
Andrew Kolbasovsky, PsyD, MBA
Determining return on investment and improvement of outcomes is essential when new programs are being tried, but the research method must be chosen carefully

Pages